An official website of the United States government Here's how you know

The .gov means it's official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Drugs@FDA: FDA-Approved Drugs

Home | Previous Page

New Drug Application (NDA): 022030
Company: PFIZER

Summary Review

Products on NDA 022030

Drug Name	Active Ingredients	Strength	Dosage Form/Route	Marketing Status	TE Code	RLD	RS
TOVIAZ	FESOTERODINE FUMARATE	4MG	TABLET, EXTENDED RELEASE;ORAL	Prescription	AB	Yes	No
TOVIAZ	FESOTERODINE FUMARATE	8MG	TABLET, EXTENDED RELEASE;ORAL	Prescription	AB	Yes	Yes

Approval Date(s) and History, Letters, Labels, Reviews for NDA 022030

Original Approvals or Tentative Approvals

Action Date	Submission	Action Type	Submission Classification	Review Priority; Orphan Status	Letters, Reviews, Labels, Patient Package Insert	Notes	Url
10/31/2008	ORIG-1	Approval	Type 1 - New Molecular Entity	STANDARD	Label (PDF) Letter (PDF) Review Summary Review (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022030lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2008/022030s000ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022030s000TOC.cfm https://www.accessdata.fda.gov/drugsatfda_docs/summary_review/2008/022030s000_SumR.pdf

Supplements

Action Date	Submission	Supplement Categories or Approval Type	Letters, Reviews, Labels, Patient Package Insert	Note	Url
02/28/2024	SUPPL-23	Labeling-Package Insert	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022030s022s023lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/022030Orig1s022,023ltr.pdf
02/28/2024	SUPPL-22	Labeling-Package Insert	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022030s022s023lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/022030Orig1s022,023ltr.pdf
06/17/2021	SUPPL-19	Efficacy-New Patient Population	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/022030s019lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/022030Orig1s019ltr.pdf
11/12/2017	SUPPL-14	Labeling-Package Insert	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022030s014lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/022030Orig1s014ltr.pdf
01/26/2017	SUPPL-12	Manufacturing (CMC)		Label is not available on this site.
01/23/2013	SUPPL-11	Manufacturing (CMC)		Label is not available on this site.
08/13/2014	SUPPL-10	Manufacturing (CMC)		Label is not available on this site.
08/01/2012	SUPPL-9	Labeling-Package Insert	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022030s009lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2012/022030Orig1s009ltr.pdf
12/30/2011	SUPPL-8	Labeling-Package Insert	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022030s008lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2011/022030s008ltr.pdf
02/10/2011	SUPPL-7	Labeling	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022030s007lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2011/022030s007ltr.pdf
11/01/2011	SUPPL-6	Labeling-Package Insert	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022030s006lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2011/022030s006ltr.pdf
04/02/2010	SUPPL-4	Labeling	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022030s004lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2010/022030s004ltr.pdf

Labels for NDA 022030

Action Date	Submission	Supplement Categories or Approval Type	Letters, Reviews, Labels, Patient Package Insert	Note	Url
02/28/2024	SUPPL-23	Labeling-Package Insert	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022030s022s023lbl.pdf
02/28/2024	SUPPL-22	Labeling-Package Insert	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022030s022s023lbl.pdf
06/17/2021	SUPPL-19	Efficacy-New Patient Population	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/022030s019lbl.pdf
11/12/2017	SUPPL-14	Labeling-Package Insert	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022030s014lbl.pdf
08/01/2012	SUPPL-9	Labeling-Package Insert	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022030s009lbl.pdf
12/30/2011	SUPPL-8	Labeling-Package Insert	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022030s008lbl.pdf
11/01/2011	SUPPL-6	Labeling-Package Insert	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022030s006lbl.pdf
02/10/2011	SUPPL-7	Labeling	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022030s007lbl.pdf
04/02/2010	SUPPL-4	Labeling	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022030s004lbl.pdf
10/31/2008	ORIG-1	Approval	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022030lbl.pdf

Therapeutic Equivalents for NDA 022030

TOVIAZ

TABLET, EXTENDED RELEASE;ORAL; 4MG
TE Code = AB

Drug Name	Active Ingredients	Strength	Dosage Form/Route	Marketing Status	RLD	TE Code	Application No.	Company
FESOTERODINE FUMARATE	FESOTERODINE FUMARATE	4MG	TABLET, EXTENDED RELEASE;ORAL	Prescription	No	AB	204973	ALEMBIC
FESOTERODINE FUMARATE	FESOTERODINE FUMARATE	4MG	TABLET, EXTENDED RELEASE;ORAL	Prescription	No	AB	204827	ALKEM LABS LTD
FESOTERODINE FUMARATE	FESOTERODINE FUMARATE	4MG	TABLET, EXTENDED RELEASE;ORAL	Prescription	No	AB	205002	AMNEAL PHARMS NY
FESOTERODINE FUMARATE	FESOTERODINE FUMARATE	4MG	TABLET, EXTENDED RELEASE;ORAL	Prescription	No	AB	204504	ANI PHARMS
FESOTERODINE FUMARATE	FESOTERODINE FUMARATE	4MG	TABLET, EXTENDED RELEASE;ORAL	Prescription	No	AB	205007	AUROBINDO PHARMA
FESOTERODINE FUMARATE	FESOTERODINE FUMARATE	4MG	TABLET, EXTENDED RELEASE;ORAL	Prescription	No	AB	204975	DR REDDYS
FESOTERODINE FUMARATE	FESOTERODINE FUMARATE	4MG	TABLET, EXTENDED RELEASE;ORAL	Prescription	No	AB	204792	HETERO LABS LTD V
FESOTERODINE FUMARATE	FESOTERODINE FUMARATE	4MG	TABLET, EXTENDED RELEASE;ORAL	Prescription	No	AB	204946	ZYDUS PHARMS
TOVIAZ	FESOTERODINE FUMARATE	4MG	TABLET, EXTENDED RELEASE;ORAL	Prescription	Yes	AB	022030	PFIZER

TABLET, EXTENDED RELEASE;ORAL; 8MG
TE Code = AB

Drug Name	Active Ingredients	Strength	Dosage Form/Route	Marketing Status	RLD	TE Code	Application No.	Company
FESOTERODINE FUMARATE	FESOTERODINE FUMARATE	8MG	TABLET, EXTENDED RELEASE;ORAL	Prescription	No	AB	204973	ALEMBIC
FESOTERODINE FUMARATE	FESOTERODINE FUMARATE	8MG	TABLET, EXTENDED RELEASE;ORAL	Prescription	No	AB	204827	ALKEM LABS LTD
FESOTERODINE FUMARATE	FESOTERODINE FUMARATE	8MG	TABLET, EXTENDED RELEASE;ORAL	Prescription	No	AB	205002	AMNEAL PHARMS NY
FESOTERODINE FUMARATE	FESOTERODINE FUMARATE	8MG	TABLET, EXTENDED RELEASE;ORAL	Prescription	No	AB	204504	ANI PHARMS
FESOTERODINE FUMARATE	FESOTERODINE FUMARATE	8MG	TABLET, EXTENDED RELEASE;ORAL	Prescription	No	AB	205007	AUROBINDO PHARMA
FESOTERODINE FUMARATE	FESOTERODINE FUMARATE	8MG	TABLET, EXTENDED RELEASE;ORAL	Prescription	No	AB	204975	DR REDDYS
FESOTERODINE FUMARATE	FESOTERODINE FUMARATE	8MG	TABLET, EXTENDED RELEASE;ORAL	Prescription	No	AB	204792	HETERO LABS LTD V
FESOTERODINE FUMARATE	FESOTERODINE FUMARATE	8MG	TABLET, EXTENDED RELEASE;ORAL	Prescription	No	AB	204946	ZYDUS PHARMS
TOVIAZ	FESOTERODINE FUMARATE	8MG	TABLET, EXTENDED RELEASE;ORAL	Prescription	Yes	AB	022030	PFIZER

Top